RespireRx Pharmaceuticals Inc (CE) (RSPI) Cotización

The more I think about it, your comment about them not wanting to utilize any of the common shares is interesting, maybe someone is prepping to take the endeavourRx division or possibly all of RSPI onto another exchange and having common mostly fixed to negotiate with all stakeholders including debt holders and other entities due money for services is all part of the process? Any new investors would probably want to understand their equity position as these candidates enter into clinical trials.

I guess we'll have to wait and see.. Sooner than later I hope.

Yeah, it feels like timing should be about right to start to see some engagement and moving the ball forward.

As noted, they have had 8+ months to iron out any details as to what is transpiring with any partnerships and funding sources in the background. Hoping to hear or see what was presented at microcap conference, although an all encompassing PR with pipeline updates and forward strategy would be great as well. I find it interesting they did not attend a biotech showcase, rather a microcap conference loaded with NASDAQ companies. My take is they have a good feel who would be potential partners to hand the baton off of the various candidates and indications, but gathering as much institutional investor support is probably a priority.

You know guys, the interface between science and business is murky to us all, I being on the science side and recently coming across a Gary Lynch paper of the late '90s on ampakines with a Google estimate of 300 citations absolutely boggles my mind. My best paper has a little over 50. Huge number of research all of the world are working and publishing on ampakines. And RSPI has tapped into all this preclinical research. This is nothing like where we were with Cortex. I believe our holdings based on where we are will be worth thousands, but of I am only expert in half of this equation.

Fingers crossed, off topic I wrote the Doctor who was to be in charge of the trials , below is all I asked , no replie as of today .

To:
msandhu@ric.org

Wed, Jan 22 at 7:20 PM

Hello ,

I am reaching out to see if you could let me know if the study below has started or when it will and how long one of theses studies take to produce results. Thank you for your time and the great work you do.
RespireRx Pharmaceuticals Inc. is delighted to announce that the Department of Defense (DOD) has approved a $1.8 million translational research award to Shirley Ryan AbilityLab to fund a two stage Phase 2A and 2B clinical study.
Sorry I left this out , I know your busy and doing alot . It was for Phase 2A and 2B clinical study in order to determine the safety and efficacy of CX1739, its lead clinical AMPAkine, to improve bladder function and motor activity in individuals with spinal cord injury.
Hopefully you can provide any news you can , that may or may not be if this isn't involved in an NDA due to the DOD . Hope you can if not I will understand a short reply of any kind would be great Again thank you

Yes you are correct , I had recalled it as them having stock but it was the board acting as the audit and that payment was due to seperate them . My mistake. It might be that they have been in talks and it was easier to go to EM and not have to do as many filings while in talks. Hopefully it is just that and now they have a plan and maybe results from any testing that has been done over the last 8 months . GLTA

That didnt say anything about needing funds and that argument was especially odd anyhow when a BOD member supplied 100k loan 10 days later according to filings.

Gotta wonder then if some entity didn't come in and there is/was a NDA put in place to negotiate the future. That would explain all the silence and lack of filing and lack of presentation and such. But for the company to allow all the egg on their face and all the delay in building out the resources, (which delays erode value), well there must be a significant plan forward in the background.

I thought it was mainly something about having them pay their debt to the accounting firm so they are truly independent. If they were given preferred shares they would never be independent, correct?

Not wanting to use common shares is polar opposite of 99.9% of OTC stocks and the entire purpose of being a publicly traded entity (i.e. raise funds for building the corporation)... We on this forum have speculated what may be going on, but I find it curious that they just now are starting to attend investor conferences and looking to engage shareholders once again. I wonder if they were negotiating funding or with BP the past 8 months of silence and now in the final stages of that and they are looking to start building investment community support. The need some funds to support clinicals even with the government funds.

PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
RespireRx Pharmaceuticals Inc. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Annual
Report on Form 10-K for the period ended December 31, 2023 (the “Annual Report”) by the April 1, 2024 filing date
applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements
due to additional time needed for the Board of Directors (acting as the Audit Committee) of the Registrant to complete its
review of the Annual Report with the Registrant’s independent registered accounting firm. As a result, the Registrant is still in
the process of preparing disclosures and accumulating validating information needed to complete the Annual Report. The
Registrant intends to file a complete Annual Report as soon as practicable within the extension period of fifteen calendar days
provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

Still digging

Remember they stated it was a conflict of interest for the firm to certify the filings, I believe they were given perfered shares for their work dont hold me to that but it was listened for the reason they could not use them .Would have to go back and find that . When I questioned them on how much they would need it was 100-150k i asked if i put together a group of us what would we get in exchange and gurantee that they would be able to then keep current. I wanted 50m in shares min per how many people we put together, they wanted to talk more but didnt want common shares involved and could say they could stay current after that. Then when I asked again after more filings were missed while on EM Jeff said it would be 200-250k know to get all filings current not to long ago. Now approching 300k I posted that when he told me that. One concern for me if they selloff sections of RSPI we really dont see value if we are on the EM , value could go up and we really cant trade as if it was on a trading tier for all. GLTA

bigtalan

Re: LTListener post# 52649

Monday, January 06, 2025 11:05:15 AM

Post#
52652
of 52884
Yes when talking about investing in it , it is clear it is seprate. I have asked many times about any updates and the look the entire company has presented for over 6 months and it really isn't the look an investor is looking for. They always offer to setup a call with Jeff to answer questions, and I tell them we have talked to Jeff and nothing is cleared up , nothing new is offered and no follow thru has taking place. They then offer to set something up, I dont think they get that talking is not getting anything positive out , it instead is keeping us all in the dark about where the company is currently and has been for 6+ months. The whole time the cost of getting current keeps increasing as it was presented to me about needing 100+150k to the last statement of 200+250k. GLTA
bigtalan

Re: None

Thursday, November 28, 2024 10:07:06 AM

Post#
52402
of 52884
Here is what I got today from the investor group I posted awhile back and my reply . The reply he sent contains basically same info I posted awhile back that Jeff had talked about.
Hi XXXX,
Trust all is well.
I caught up with the company last week to press them on their SEC filings. Please find their response below
“With respect to getting current with our SEC filings, we would require approximately $150,000 and it would take approximately two month (subject to staff availability at our auditors) to catch up on the 31 Dec 2023 annual report and three quarterly reports. The $150K would be sufficient for us to complete timely (possibly on extension), the 31 Dec 2024 annual report.”
The company is cash-strapped, hence why it’s taking time to get their filings up to date. Would this be something you could potentially support if there was a meaningful equity component as an incentive?

Please let me know your thoughts.
Best Regards,
XXXX

Thanks I have been in talks with Jeff , I knew of the need for cash.

What I and other investors have concerns is with all the grants they have and positive results that they have released why no big invetsor or Big Pharm hasnt stepped in. The share structure that he was talking about to me just isnt enough to take more of a risk along with no gurantee they would come off EM and not return to it mid year. They could have gone a different direction than the EM , instead they went there, now they have no real way of trading to raise money. Many of us would have rather them have diluted a small amount of shares and stay on the OTC so it could have traded and build up the share price not collapse it on the EM. If we took the class shares he was talking about we would be stuck with shares that we would not be able to sell easily. I already have 15M shares at an average of .00098 and I am holding but to put in a 10k - 25k additional investment is not on my table.

Thanks for your response and have a great holiday season
Bullish
Bullish

Seems odd.

The accounting firm owns shares of RSPI? I thought they supposedly didn't have the cash at that time? $300-$350k doesnt seem right either. I think in the past they only needed $100-$150k for a year and why is it now so expensive? Doesn't sound like they are interested in coming off the EM, so if they are out marketing to intitutional level interests, there must be another path they are pursuing.. M&A possibly?

If they are keeping everything around 80% complete , if using the same accountant firm I would say maybe 3 weeks. If they leave the accountant firm for a new one I would say more like 4-6 weeks due to a total review. I still think the current one would be owed money due to them being paid by interest in the company. Reason why they couldnt file in the first place conflict of interest. Them holding a interest in the company. So they keep stating the magic # 300-350k the question is does that result the issue and they are used , or is that to pay a new company to review and write the letter for them and the old company retains the interest in RSPI. GLTA My thoughts go out to all the victims and the families of lastnights tradegy

It doesnt seem like their filings should be that difficult so I don't have a clue how long the process would take. Seems like the missing 10-k and 10-q's could all be done in a week or two especially if they are 80% the way there and it is not like they are that complex of a corporation.

If this continues to trade on the EM while simultaneously getting caught up on filings and seeking institutional and microcap investors while also having updates about clinicals come in, there could be accumulation of shares while on the EM that rises the pps. Some have suggested this could be a penny or two by the time they officially get off the EM.

You stated…“….Will many sell at .01 knowing they can’t get shares back that could be worth 10-20x more?…. “

Why would they not be able to get shares back after they sell again?

Last they stated they were 80% complete on files , but that was a qrt ago , plus the year end filings . Hopefully they have been. GLTA.

Hopefully they are keeping up on paperwork for quicker exit from EM. Although maybe “experts” will come in and acquire all scraps folks are willing to part with up to a penny or two?

Will many sell at .01 knowing they can’t get shares back that could be worth 10-20x more?

It jumped because the expert market it sucks. Tomorrow it will most likely be right back down to .0006 with 100 shares.
Nothing is for Real on the expert market.

I can't wait for them to bring us current again. Once we are off the expert market when we get a nice price jump then we can get excited for Real.
Right now, just expect violent price moves with no reason behind it.

Thanks LT, waiting for it to come out of EM. Thought I missed that it's finally coming out of EM :)) hopefully soon. 

I would guess they are looking for institutional investors with long term mindset and not someone looking to flip shares on momentum.

With that said, institutional would still want to see a plan for liquidity. Maybe take a few off the table every nickel increase over next few years and ride some % to see if KRM-ll-81 becomes blockbuster status progressing thru clinicals.

Maybe they have explanation for EM move.

Nah what surprises me more they go to investing events to generate interest in their products yet if some individual non organization facilitated asks where they can invest in they gotta tell them sorry but we currently are off the market in the u.s due to us not being able to pay our auditors and can only be bought in canda as such lol.

I am saying I would have like a .24 instead of .0024

We've seen those micro trades before. I don't get it why bother? .24 trade ?

Yes today at 2 or 230 if I remember

I think they were presenting today at the microcap conference, so maybe we will see a bit of interest show up. It still surprises me they go into these conferences and presentations with that crappy outdated website. Although maybe this is just simply about carrying around a glass slipper and see who it fits!

Volume of a 100 easy to make it move . Hopefully the presentation went well a hour ago. Wish it was .24 in this account GLTA
Last Price $ Change $ Change % Qty # Price Paid $ Day's Gain $ Total Gain $ Total Gain % Value $
0.0024 0.0013 118.18% 11,640,000 0.00114 15,132.00 14,595.70 109.41% 27,936.00

The current trading on this expert market is meaningless as there is no volume and liquidity. I would not read much into it.

Why this huge jump?

Well, they need to revive the communication, presentation and liquidity first.

But to my point, if this was trading at reasonable valuation, they could have flexibility to explore any avenues that could revive the high impact ampakine portfolio. Until they get the corporation better positioned however, I expect they would hopefully focus on the immediate tasks at hand and the prospects of getting CX-1739 and KRM-ll-81 into clinical trials ASAP.

Methinks RSPI needs to revive the CX929 patent

Neuropharmacology Available online 24 January 2025, 110322

Neurobiology, Molecular Pathways, and Environmental Influences in Antisocial Traits and Personality Disorders.

Patryk M. Adamczyk 1, Andrew Shaw 2, Ilaria M. Morella 3 4, Lorenzo More 1

https://doi.org/10.1016/j.neuropharm.2025.110322Get rights and content
Abstract
Personality disorders (PDs) are psychiatric conditions characterized by enduring patterns of cognition, emotion, and behaviour that deviate significantly from cultural norms, causing distress or impairment. The aetiology of PDs is complex, involving both genetic and environmental factors. Genetic studies estimate the heritability of PDs at 30% to 60%, implicating genes involved in neurotransmitter regulation, such as those for serotonin transporters and dopamine receptors. Environmental factors, including childhood trauma and chronic stress, interact with genetic predispositions to induce epigenetic modifications like DNA methylation and histone modifications, contributing to PD development.
Neurobiological research has identified structural and functional abnormalities in brain regions related to emotional regulation and social cognition, such as the amygdala, prefrontal cortex, and limbic system. These abnormalities are linked to impaired emotion processing and interpersonal functioning in PDs. This review focuses on how environmental factors shape maladaptive behaviours and endophenotypes central to many PDs. It explores the interaction between the Ras-ERK, p38, and mTOR molecular pathways in response to environmental stimuli, and examines the role of oxidative stress and mitochondrial metabolism in these processes.
Also reviewed are various types of PDs and existing animal models that replicate key endophenotypes, highlighting changes in neurotransmitters and neurohormones. Identifying molecular biomarkers can lead to the development of "enviromimetic" drugs, which mimic environmental influences to activate molecular pathways, facilitating targeted, personalized treatments based on the molecular profiles of individuals with PDs. Ultimately, understanding the molecular mechanisms of PDs promises to enhance diagnostic accuracy, prognosis, and therapeutic outcomes for affected individuals.
5.1. CX929 ampakine as unspecific Ras-ERK potentiator
Ampakines can cross the blood-brain barrier and exhibit neuroprotective properties, potentially offering therapeutic benefits in a range of neurological and psychiatric disorders, (Simmons et al., 2011) although their potential in enhancing sociability remains still unexplored.
Ampakines are a class of compounds that enhance synaptic transmission by modulating the activity of AMPA receptors. The mechanism of action of ampakines involves the positive allosteric modulation of AMPA receptors and unlike direct agonists, ampakines bind to a distinct site on the receptor, enhancing its response to endogenous glutamate without directly activating the receptor (Lauterborn et al., 2016).
Upon binding to the allosteric site, ampakines stabilize the open state of the AMPA receptor channels, increasing their conductance and prolonging the duration of excitatory postsynaptic currents (EPSCs). This results in an increased influx of sodium ions (Na+) and, to a lesser extent, calcium ions (Ca2+), leading to enhanced synaptic strength and plasticity. This mechanism facilitates long-term potentiation (LTP) (Rex et al., 2006).
Ampakines also reduce receptor desensitization, allowing for sustained receptor activation during repetitive synaptic activity. This effect is particularly beneficial in enhancing cognitive functions, as it promotes more efficient synaptic transmission and communication within neural networks involved in learning and memory processes (Seese et al., 2020).
Ampakines activate the Ras-ERK pathway via increasing calcium-dependent signalling which activates Ras which in turn initiates the MAPK/ERK pathway by activating Raf kinase, which in then phosphorylates and activates MEK (MAPK/ERK kinase) (Kramar et al., 2012).
MEK-induced ERK phosphorylation leads to ERK activation and its subsequent translocation into the nucleus, where ERK phosphorylates various transcription factors such as CREB, via the action of MSK1, and eventually enhances the transcription of genes involved in synaptic plasticity, neuronal survival, and growth (Hunter et al., 2017; Cooper and Frenguelli, 2021).

Maybe. But it seems like the otc lacks both the liquidity and the institutional support that these drug candidates heading into clinical trials both need and deserve.

Excited to hear where they are going with everything. Hopefully soon.

Maybe this gets us back to US markets? https://blog.otcmarkets.com/2024/10/14/the-evolution-of-the-otc-market-introducing-otcid/

Certainly plausible years down the road if they get through a few levels of clinicals and one of their platforms become blockbuster for mitigating opioids or treatment of epilepsy, ADHD, OSA, etc...

A lot of resource build out and clinical success necessary (without giving away too much asset equity) between now and then. They just need to get going. Some funding and partnerships would go a long way in building and sustaining a more representative market valuation which then opens the door to further resource build out and the flexibility to capitalize efficiently on clinical success and then let success breed success when it comes to market valuation!

Hell, LT, I would be surprised if we aren't in the 1-to-2-dollar range when things finally shake out

I think it is very hard to predict.

This company has been so undervalued for so long. You can think .01-.02 range, but that is merely a 10-20 million market cap today and even if fully diluted status would require using the entire 2B authorized, that is only then 20-40 million valuation. That is what they claim the OSA program alone is worth!

Pharma's can easily trade for 100's of million and there are plenty of stories of OTC pharma with much much less in terms of asset/potential trading at very high market valuations. Granted OTC is not as liquid today as it has been in the past.

My opinion is that KRM-ll-81 has blockbuster potential coming out of preclinicals. If clinical trials for epilepsy and/or pain can match the excitement shown by the execs and publication commentary, then sky is literally the limit.

We need to hear updates, see filings, get clinicals initiated to get a better feel as to where all this is at and going.

IMO, any merger or plans to get to a more liquid market (what institutional investors would want) would only happen if the merger provided much more resources for this company. Obviously, cash resources are needed, but more importantly capabilties in terms of experience, people, etc. Below is the language they have used in many filings...

"The Company’s business development efforts (licensing, sub-licensing, joint venture and other commercial structures), if successful, would represent strategic and operational infrastructure additions, as well as cash and in-kind funding opportunities. These efforts have focused on, but have not been limited to, transacting with brand and generic pharmaceutical and biopharmaceutical companies as well as companies with potentially useful clinical development, formulation or manufacturing capabilities, significant subject matter expertise and financial resources."

They speak also of spinning out neuromodulator platform. Could there be a listed reverse merger candidate that has resources but not very viable assets? Or simply could they partner with BP and underpin valuation and then take steps to get there on their own? Considering they have phase 2 funding secured and hopefully trial initiation soon AND the NIH preclinical success could lead KRM-ll-81 down multiple paths both for epilepsy and pain, there very well could be a partnership looming and a needed carrot to dangle when presenting with institutional investors.

Atleast it is looking better and we are hearing alot more than we were. They present tomorrow so hopefully Jeff gets something together by VDay . GLTA

Yeah I got 7m 0022 average I firmly believe just from their pipeline if we get current we open and run far into cents probably settle high 1's or low 2's unless BP deal is secured or clinicals phase 2 are progressing without hiccups. Also they said in q1 for 2025 ATT should get back to them with sources of funding

The other path could be a SPAC not that I am a fan , if the right one is found and it works for them no complaints. I do like the Reg A Offering pathway sounds alot easier and quicker. I am at a break even point on my holdings .00114 avg GLTA

I agree.

Status of pipeline progress.
Plans to get off expert market.

From there they can then PR continual updates on conferences/website engagement efforts, collaborations, clinical initiatives and eventually clincal results, partnerships, license/JV, etc, etc.

No matter what comes from the conference we need to hear what plans are in the works to come off the expert market. The first item to be completed to get the true valuation.

Possibly. A few years back they tried a reg A offering. They might have something similar planned to grab as much institutional investment as possible to support as these candidates enter clinical trials. I could see too that they have a license/partnership deal in the works as well which as discussed here may have been source of the silence. Otherwise, why not hit the conference circuit last June??

Either way sounds like investor engagement is forthcoming which is a very good sign to all stakeholders.

I find it very interesting that Jeff stated the following.

"We are likely to be presenting at other conferences as well during Q1 2025."

This certainly leads me to believe that multiple deals may come to fruition.

I do find it a bit interesting that after all this silence, once again RSPI is presenting at now a microcap conference, yet they did not participate in a recent biotech conference mentioned on this forum a few weeks ago? hmmm.. Obviously, if you are going to be mingling with institutional level investors, there must be something meaningful and interesting to present. Hopefully we are on the cusp of the necessary transformation for these assets to become company making and supported properly. GLTA.

I still have all mine to . I'll wait them out !

Cooked

These type of events can highlight how undervalued their assets are. Positioned to have multiple candidates into clinical trials with government funding is a big deal and certainly should value this company well beyond market cap range for past several years.

I am interested in hearing more detail and clarity as to the approach with the candidates on all 3 platforms. I think the SCI trial leads into ADHD which makes sense. Not sure why there has been zero progress on OSA platform. Really interested in seeing how well KRM-ll-81 stacked up in NIH preclincals and if there is a simultaneous approach to get that one into both epilepsy and pain clinical trials.

Outside of that, what is the strategy to achieve sustainable fair market valuation which would open up a significant amount of doors for resource building to support these platforms and possibly branch out. They have had ample time to formulate a strategy and re-engaging investors is likely to first step of many many months of unveiling go forward strategies and progress updates as clinicals kick off.

Big newes even a PR from this event just from them presenting alongside so many nasqad tickers would've drove this to cents if we were current. Hopefully the upcoming newes gives us a clear direction or a peek into all that is hiding behind the curtain.

That will be an interesting facet of re-engaging stakeholders as to how they anticipate re entering a liquid market for shares.

Many of us on this forum have speculated they may be spinning an asset out or looking at possible methods to merge to another exchange.

Well this sounds positive. They appear to be planning on re-engaging the investment world!

And they should have a very nice story to tell with the progress of their candidates…. Sprinkle in some funding and/or partnerships and get some clinical trials rolling and there will be a company making transformation. Oh and update that website!